• The stock target price for Waldencast plc (NASDAQ:WALD) has been adjusted from $4.13 to $3.25, with D.A. Davidson setting a more optimistic target of $15.50.
• Waldencast reported a net revenue of $65.4 million for Q1 2025, a decline of 4.1% year-over-year, alongside an adjusted gross margin of 76.4% and an adjusted EBITDA of $4.4 million.
• The company is facing margin pressure and negative earnings, attributed to high SG&A expenses and significant debt, yet maintains manageable liquidity and a long debt maturity timeline extending to 2030.

Waldencast plc (NASDAQ:WALD) is a skincare company renowned for its advanced skincare treatments. Established in 1988 and headquartered in White Plains, New York, Waldencast provides products through dermatologists and skincare professionals. Its portfolio includes notable brands such as Obagi Medical and Obagi Clinical, aimed at addressing skin concerns like aging and hyperpigmentation.

The stock target price for Waldencast has experienced a downward adjustment from $4.13 last year to $3.25 in recent months. This change reflects a shift in analysts' expectations, potentially due to market conditions or company performance. Despite this, D.A. Davidson has set a higher price target of $15.50, indicating a more optimistic outlook.

Waldencast is currently facing margin pressure and negative earnings, primarily due to high SG&A expenses and significant debt. The company reported a net revenue of $65.4 million for Q1 2025, marking a 4.1% decline from the previous year. However, it achieved an adjusted gross margin of 76.4% and an adjusted EBITDA of $4.4 million.

The company held its Q1 2025 earnings call on May 14, 2025, featuring key figures such as CEO Michel Brousset and CFO Manuel Manfredi. Analysts from firms like Alliance Global Partners and TD Cowen participated, offering insights into Waldencast's financial performance and strategic direction.

Waldencast's financial profile is indicative of a high-growth company, characterized by negative cash flow and high leverage. Despite these challenges, the company maintains manageable liquidity and a long debt maturity timeline extending to 2030. Investors are advised to consider these factors in conjunction with target price trends when evaluating Waldencast's stock.